Nuventra
Nuventra is a drug development consulting firm providing clinical pharmacology, pharmacokinetics, and regulatory strategy services, operating within the Allucent full-service CRO platform that serves small and mid-sized biotech companies across the drug development lifecycle.
- Company typePrivate
- Founded2008
- HeadquartersCary, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Nuventra does
Nuventra is a drug development consulting firm founded in 2008 and headquartered in Cary, North Carolina, with an employee base of 51-100. The company provides specialized clinical pharmacology and drug development consulting services, and the available data indicates it operates within the broader Allucent platform — a global full-service contract research organization (CRO) serving small and mid-sized biotech and biopharma companies. Its services span the entire drug development lifecycle, from early-stage discovery through clinical development and post-marketing approval, with core competencies in pharmacokinetics, modeling and simulation, and regulatory strategy.
The platform's technical and service surface includes clinical development (study start-up, the IGNITE clinical research site network, patient recruitment and retention, decentralized clinical trials, data management, biostatistics, and medical monitoring), clinical pharmacology (drug development strategy, modeling and simulation, end-to-end pharmacokinetics, and embedded pharmacologist support), regulatory strategy (CMC/preclinical, clinical strategy, regulatory submissions, and GxP consulting), and drug safety/pharmacovigilance. Therapeutic specialization is organized around centers of expertise in oncology and hematology, neuroscience, infectious disease and vaccines, immunology and inflammation, cardiometabolic disease, rare diseases, and cell and gene therapy.
The business model is professional-services based: revenue is generated through contract research and consulting engagements priced per project rather than via publicly disclosed rates. Go-to-market is an enterprise/field consultative sales motion using "Schedule a Consultation" and "Request a Proposal" engagement paths, supported by content marketing (blogs, white papers, case studies), webinars, podcasts, industry events, and organic social. The primary customer base is small and mid-sized biotech companies that lack internal resources for complex, multi-region clinical development and require specialized therapeutic and regulatory expertise.
Nuventra firmographics
Firmographics- Name
- Nuventra
- Website
- https://nuventra.com
- Company type
- Private
- Founded year
- 2008
- Headcount range
- 51–100 employees
- Short description
- Nuventra is a drug development consulting firm providing clinical pharmacology, pharmacokinetics, and regulatory strategy services, operating within the Allucent full-service CRO platform that serves small and mid-sized biotech companies across the drug development lifecycle.
- Ownership category
- akta.pro rank
Where Nuventra is headquartered
LocationHeadquarters
- HQ city
- Cary
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Nuventra business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Contract Research Services: Allucent provides contract research organization (CRO) services to biotech and biopharma companies, offering clinical development, clinical pharmacology, regulatory strategy, and drug safety services. Revenue is generated through service contracts for clinical trials and consulting engagements across all phases of drug development.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Nuventra product offering
Product offeringCore offering
Nuventra offers drug development consulting services for pharmaceutical and biotechnology clients, spanning clinical pharmacology, pharmacokinetics, regulatory strategy, clinical development, drug safety/pharmacovigilance, and government/public-health programs. The firm combines scientific consulting with clinical operations (including decentralized clinical trial capabilities and a proprietary investigator/site network) to guide assets from preclinical planning through regulatory submission and post-marketing.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Development Services
Quantifiable outcome
- 105+ successful marketing applications and approved products
- +4 more outcomes
Companies that use Nuventra
Customer profileSegments9 records
Ideal customer profiles2 records
Nuventra technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nuventra partnerships and signals
Strategic signalScale indicators9 records
Recent moves4 records
Expansion highlights5 records
Nuventra competitors and assessment
Company assessmentDirect peers
- Simulations Plus: Simulations Plus provides modeling-and-simulation software and services for PK/PD, physiologically-based pharmacokinetics, and quantitative systems pharmacology — closely overlapping with the clinical pharmacology consulting core of Nuventra.
- Certara: Certara is a leading biosimulation and clinical pharmacology services/software firm providing PK/PD modeling, regulatory science, and drug development consulting — a near-direct analog to Nuventra's clinical-pharmacology focus, scaled larger and publicly traded.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with strong scientific and clinical-pharmacology depth targeting small and mid-sized biotech — closely comparable size, customer profile, and therapeutic mix to Nuventra.
Broad incumbents
- Syneos Health: Syneos Health is a large CRO with end-to-end clinical development and clinical pharmacology services competing for biotech Phase I-III work that overlaps Nuventra's target engagements.
- IQVIA: IQVIA is the largest global CRO and clinical pharmacology provider with extensive biosimulation and regulatory capabilities — represents the scaled incumbent end of the spectrum Nuventra competes within for biotech clinical development work.
- Charles River Laboratories: Charles River provides preclinical through clinical drug development services including safety, pharmacology, and regulatory consulting — an adjacent competitor in the drug-development consulting space serving similar biotech clients.
- ICON plc: ICON is a top-three global CRO with deep biotech focus post-PRA Health Sciences acquisition, offering end-to-end clinical development and clinical pharmacology services overlapping Nuventra's value proposition.
- Pharmaceutical Product Development (PPD): PPD (now part of Thermo Fisher Scientific) is a global CRO offering clinical pharmacology, modeling-and-simulation, and biotech-focused drug development services — a scaled incumbent competitor for the same customer segment.
- Allucent: Allucent is the broader full-service CRO whose service portfolio (clinical pharmacology, clinical development, regulatory strategy) encompasses Nuventra's niche; the firmographics and dataset strongly suggest Nuventra operates within or alongside Allucent.
- Medpace: Medpace is a mid-to-large full-service CRO with strong scientific/medical credibility serving small and mid-sized biotechs — directly comparable customer base and increasingly overlapping clinical-pharmacology capabilities to Nuventra.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks4 records
Key highlights4 records
Customer concentration
Nuventra social profiles
Digital presenceNuventra financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nuventra leadership team
Management profileNumber of profiles
Profiles2 records
Nuventra funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nuventra M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nuventra
What does Nuventra do?
Nuventra offers drug development consulting services for pharmaceutical and biotechnology clients, spanning clinical pharmacology, pharmacokinetics, regulatory strategy, clinical development, drug safety/pharmacovigilance, and government/public-health programs. The firm combines scientific consulting with clinical operations (including decentralized clinical trial capabilities and a proprietary investigator/site network) to guide assets from preclinical planning through regulatory submission and post-marketing.
When was Nuventra founded?
Nuventra was founded in 2008. It employs 51 to 100 people.
Where is Nuventra based?
Nuventra is headquartered in Cary, United States, in the North America region.
How does Nuventra make money?
One revenue line is on record: contract Research Services.
Who are Nuventra's main competitors?
Direct peers on record are Simulations Plus, Certara and Worldwide Clinical Trials. Broad incumbents are Syneos Health, IQVIA, Charles River Laboratories, ICON plc, Pharmaceutical Product Development (PPD), Allucent and Medpace.
Does Nuventra have an API?
No public API is recorded for Nuventra.